These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19657689)

  • 21. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.
    Simon JA; Lewiecki EM; Smith ME; Petruschke RA; Wang L; Palmisano JJ
    Clin Ther; 2002 Nov; 24(11):1871-86. PubMed ID: 12501880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
    Hooper M; Faustino A; Reid IR; Hosking D; Gilchrist NL; Selby P; Wu M; Salzmann G; West J; Leung A
    Osteoporos Int; 2009 Jan; 20(1):141-50. PubMed ID: 18536953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab: new horizons in the treatment of osteoporosis.
    Wilton JM
    Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
    [No Abstract]   [Full Text] [Related]  

  • 31. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
    Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
    Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
    Kendler D; Kung AW; Fuleihan Gel-H; González González JG; Gaines KA; Verbruggen N; Melton ME
    Maturitas; 2004 Jul; 48(3):243-51. PubMed ID: 15207890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study.
    Weiss M; Vered I; Foldes AJ; Cohen YC; Shamir-Elron Y; Ish-Shalom S;
    Aging Clin Exp Res; 2005 Apr; 17(2):143-9. PubMed ID: 15977463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
    Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
    Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.